Pitocin, made by New Jersey-based JHP Pharmaceuticals, is a synthetic form of the natural hormone oxytocin that regulates uterine contractions.
The rate of knee replacement surgeries each year in the United States has tripled in recent decades to almost 750,000 annually, and the number is expected to continue growing to roughly 3.5 million procedures over the next decade.
Fortunately, American consumers have never had greater access to the civil justice system and the right to seek compensation when harmed by dangerous products. And, with thousands of prescription drugs and medical devices on the market, patients have never faced more harm from side effects.
Coming off a 2016 that saw just over 20 new drugs approved for launch by the FDA, 2017 was a marked improvement - and 2018 looks to be no different. Experts are predicting several of the medications slated for launch next year could become household names.
While type 2 diabetes drugs are among the fastest-growing segment on the market, they’re not without risk of serious side effects. In just the past 5 years, studies have linked them to kidney disease, bladder cancer, pancreatitis and ketoacidosis.
In June, details emerged that DePuy’s Attune knee implant system, one of the most popular on the market, was experiencing higher-than-expected failure rates among patients.
Despite some recent positive results from a small Parkinson’s study, the leukemia medication Tasigna from Swiss drug giant Novartis has been in the news for all the wrong reasons.
With the ink barely dry on last month’s $417 million award to a California woman who developed ovarian cancer after decades of using Johnson & Johnson’s baby powder products, many are asking if they should join the litigation, and what this could mean for their case.
There’s no shortage of reports finding traces of weed killer RoundUp’s active ingredient glyphosate in some of the most popular consumer staples like cereals, crackers, chips and oatmeal.
More than seven years now since the introduction of novel oral anticoagulant (NOAC) drugs like Pradaxa, Xarelto and Eliquis, experts are still debating their safety relative to warfarin, the drug they were meant to replace.
Yet, despite the billions in sales for these medications, one thing can’t be debated: tens of thousands of patients have already been hospitalized or killed from internal bleeding after taking them.